PE20210122A1 - Composiciones de edb que se dirigen a il-12 - Google Patents
Composiciones de edb que se dirigen a il-12Info
- Publication number
- PE20210122A1 PE20210122A1 PE2020001190A PE2020001190A PE20210122A1 PE 20210122 A1 PE20210122 A1 PE 20210122A1 PE 2020001190 A PE2020001190 A PE 2020001190A PE 2020001190 A PE2020001190 A PE 2020001190A PE 20210122 A1 PE20210122 A1 PE 20210122A1
- Authority
- PE
- Peru
- Prior art keywords
- protein
- edb
- binding domain
- composition
- subunit
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000008685 targeting Effects 0.000 title 1
- 102000016359 Fibronectins Human genes 0.000 abstract 2
- 108010067306 Fibronectins Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000002067 Protein Subunits Human genes 0.000 abstract 1
- 108010001267 Protein Subunits Proteins 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invencion se refiere a composiciones que comprenden una citoquina, un dominio de union a antigeno y un enlazador mejorado o sus sales farmaceuticamente aceptables. Esta composicion comprende: a) una proteina IL-12 que comprende una primera subunidad de IL-12 y una segunda subunidad de proteina IL-12; b) una proteina que comprende un dominio de union a fibronectina EDB y; c) un enlazador entre la proteina IL-12 y la proteina que comprende el dominio de union a fibronectina EDB. Tambien se refiere a un kit terapeutico, a un polinucleotido que codifica una composicion, un vector y un metodo para elaborar un polipeptido. Esta composicion es util para el tratamiento de enfermedades neoplasicas como melanoma maligno, cancer hepatocelular, cancer gastrico, cancer cervical, entre otros.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18156141 | 2018-02-09 | ||
EP18179313 | 2018-06-22 | ||
PCT/EP2019/053136 WO2019154986A1 (en) | 2018-02-09 | 2019-02-08 | Edb targeting il-12 compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20210122A1 true PE20210122A1 (es) | 2021-01-19 |
Family
ID=65268973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020001190A PE20210122A1 (es) | 2018-02-09 | 2019-02-08 | Composiciones de edb que se dirigen a il-12 |
Country Status (22)
Country | Link |
---|---|
US (1) | US20200397915A1 (es) |
EP (1) | EP3749372A1 (es) |
JP (2) | JP7279054B2 (es) |
KR (2) | KR102259085B1 (es) |
CN (1) | CN111683687A (es) |
AU (2) | AU2019219201B2 (es) |
BR (1) | BR112020012888A2 (es) |
CA (1) | CA3087488C (es) |
CL (1) | CL2020002052A1 (es) |
CO (1) | CO2020009737A2 (es) |
CR (1) | CR20200342A (es) |
CU (1) | CU20200054A7 (es) |
EC (1) | ECSP20047171A (es) |
IL (1) | IL275713A (es) |
JO (1) | JOP20200193A1 (es) |
MX (1) | MX2020008231A (es) |
PE (1) | PE20210122A1 (es) |
PH (1) | PH12020551230A1 (es) |
RU (2) | RU2021130306A (es) |
SG (1) | SG11202006334XA (es) |
UY (1) | UY38074A (es) |
WO (1) | WO2019154986A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102524247B1 (ko) * | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3의 복합체 및 이의 용도 |
EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
WO2021209452A1 (en) | 2020-04-14 | 2021-10-21 | Philogen S.P.A. | Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain b of fibronectin |
KR102649794B1 (ko) * | 2020-10-19 | 2024-03-22 | 고려대학교 산학협력단 | 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법 |
WO2023131611A1 (en) * | 2022-01-04 | 2023-07-13 | Philogen S.P.A. | Combination of an immunocytokine comprising il-12 and a kinase inhibitor |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5994104A (en) * | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
JP2003524018A (ja) | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | フィブロネクチンのed‐bドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
ATE333900T1 (de) * | 2000-02-24 | 2006-08-15 | Philogen Spa | Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
PT1483297E (pt) | 2002-03-11 | 2010-03-29 | Philogen Spa | Anticorpos derivados de anti-ed-b l19 e direccionamento para a vasculatura tumoral |
MX2007013875A (es) | 2005-05-11 | 2008-01-28 | Philogen Spa | Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12. |
SG178443A1 (en) * | 2009-08-17 | 2012-04-27 | Roche Glycart Ag | Targeted immunoconjugates |
EP3834847A1 (en) * | 2011-07-27 | 2021-06-16 | Philogen S.p.A. | Il-12 immunoconjugate |
WO2017062953A1 (en) * | 2015-10-10 | 2017-04-13 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
AU2018226215B2 (en) * | 2017-02-24 | 2019-11-21 | Philogen S.P.A. | Immunoconjugates with optimized linkers and orientation |
-
2019
- 2019-02-07 UY UY38074A patent/UY38074A/es not_active Application Discontinuation
- 2019-02-08 CR CR20200342A patent/CR20200342A/es unknown
- 2019-02-08 CU CU2020000054A patent/CU20200054A7/es unknown
- 2019-02-08 KR KR1020207025138A patent/KR102259085B1/ko active IP Right Grant
- 2019-02-08 BR BR112020012888-0A patent/BR112020012888A2/pt unknown
- 2019-02-08 SG SG11202006334XA patent/SG11202006334XA/en unknown
- 2019-02-08 JO JOP/2020/0193A patent/JOP20200193A1/ar unknown
- 2019-02-08 WO PCT/EP2019/053136 patent/WO2019154986A1/en unknown
- 2019-02-08 RU RU2021130306A patent/RU2021130306A/ru unknown
- 2019-02-08 AU AU2019219201A patent/AU2019219201B2/en active Active
- 2019-02-08 RU RU2020127719A patent/RU2758143C1/ru active
- 2019-02-08 CA CA3087488A patent/CA3087488C/en active Active
- 2019-02-08 EP EP19702649.5A patent/EP3749372A1/en active Pending
- 2019-02-08 MX MX2020008231A patent/MX2020008231A/es unknown
- 2019-02-08 KR KR1020217015607A patent/KR102488801B1/ko active IP Right Grant
- 2019-02-08 CN CN201980012247.6A patent/CN111683687A/zh active Pending
- 2019-02-08 PE PE2020001190A patent/PE20210122A1/es unknown
- 2019-02-08 US US16/968,445 patent/US20200397915A1/en active Pending
- 2019-02-08 JP JP2020542822A patent/JP7279054B2/ja active Active
-
2020
- 2020-06-28 IL IL275713A patent/IL275713A/en unknown
- 2020-08-06 CO CONC2020/0009737A patent/CO2020009737A2/es unknown
- 2020-08-06 EC ECSENADI202047171A patent/ECSP20047171A/es unknown
- 2020-08-07 CL CL2020002052A patent/CL2020002052A1/es unknown
- 2020-08-07 PH PH12020551230A patent/PH12020551230A1/en unknown
-
2021
- 2021-06-16 AU AU2021203986A patent/AU2021203986A1/en active Pending
-
2023
- 2023-05-10 JP JP2023077703A patent/JP2023113648A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2020009737A2 (es) | 2020-08-21 |
PH12020551230A1 (en) | 2021-05-17 |
US20200397915A1 (en) | 2020-12-24 |
KR20210063467A (ko) | 2021-06-01 |
RU2021130306A (ru) | 2021-11-10 |
AU2021203986A1 (en) | 2021-07-08 |
KR102259085B1 (ko) | 2021-06-03 |
CU20200054A7 (es) | 2021-05-12 |
CR20200342A (es) | 2020-10-19 |
JOP20200193A1 (ar) | 2020-08-06 |
ECSP20047171A (es) | 2020-09-30 |
KR20200109380A (ko) | 2020-09-22 |
IL275713A (en) | 2020-08-31 |
JP7279054B2 (ja) | 2023-05-22 |
CA3087488A1 (en) | 2019-08-15 |
CA3087488C (en) | 2021-11-02 |
CN111683687A (zh) | 2020-09-18 |
TW201934136A (zh) | 2019-09-01 |
JP2023113648A (ja) | 2023-08-16 |
KR102488801B1 (ko) | 2023-01-13 |
WO2019154986A1 (en) | 2019-08-15 |
SG11202006334XA (en) | 2020-08-28 |
RU2758143C1 (ru) | 2021-10-26 |
EP3749372A1 (en) | 2020-12-16 |
UY38074A (es) | 2019-10-01 |
CL2020002052A1 (es) | 2021-01-04 |
BR112020012888A2 (pt) | 2020-12-08 |
MX2020008231A (es) | 2020-09-25 |
JP2021513536A (ja) | 2021-05-27 |
AU2019219201A1 (en) | 2020-07-23 |
AU2019219201B2 (en) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20210122A1 (es) | Composiciones de edb que se dirigen a il-12 | |
EA202090090A1 (ru) | Включение неприродных нуклеотидов и способы с ними | |
PE20181156A1 (es) | Genes de ataxia de friedreich modificados y vectores para terapia genica | |
CY1123192T1 (el) | Αντισωματα ειδικα στην κλαουδινη 6 (cldν6) | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
CO2018012096A2 (es) | Proteínas de fusión gdf15 y usos de estas | |
SV2018005661A (es) | Composiciones oligonucleotidicas y sus metodos | |
MX2023014120A (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentradas de baja viscosidad, kits, y metodos. | |
EA202190189A1 (ru) | Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты | |
CY1114050T1 (el) | Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου | |
CO2021010150A2 (es) | Inhibidores irreversibles de la interacción menina-mll | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
SA519410253B1 (ar) | Erk1/2 مشتق 6- بيريميدين أيزوإندول كمثبط | |
BR112021024236A2 (pt) | Proteínas multiespecíficas | |
PE20181049A1 (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia | |
CO2019014286A2 (es) | Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas | |
MX2021011997A (es) | Enlazadores de conjugacion mejorados. | |
CL2021000909A1 (es) | Anticuerpos estabilizadores de trem2 | |
MX2017011794A (es) | Composiciones y metodos para diagnosticos y tratamiento del cancer. | |
EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
CO2021009129A2 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
MX2021006945A (es) | Anelosomas para suministrar modalidades terapéuticas de reemplazo de proteínas. | |
PE20211225A1 (es) | Constructos de arni para inhibir la expresion de pnpla3 | |
BR112022000297A2 (pt) | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |